Related Experiment Video
Updated: Oct 5, 2025
A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation
Published on: January 9, 2019
ERDRP-0519 inhibits feline coronavirus in vitro
Michele Camero1, Gianvito Lanave2, Cristiana Catella1
1Department of Veterinary Medicine, University of Bari, Valenzano, Italy.
Background:
Coronaviruses (CoVs) are major human and animal pathogens and antiviral drugs are pursued as a complementary strategy, chiefly if vaccines are not available. Feline infectious peritonitis (FIP) is a fatal systemic disease of felids caused by FIP virus (FIPV), a virulent pathotype of feline enteric coronavirus (FeCoV). Some antiviral drugs active on FIPV have been identified, but they are not available in veterinary medicine. ERDRP-0519 (ERDRP) is a non-nucleoside inhibitor, targeting viral RNA polymerase, effective against morbilliviruses in vitro and in vivo.
Results:
The antiviral efficacy of ERDRP against a type II FIPV was evaluated in vitro in Crandell Reese Feline Kidney (CRFK) cells. ERDRP significantly inhibited replication of FIPV in a dose-dependent manner. Viral infectivity was decreased by up to 3.00 logarithms in cell cultures whilst viral load, estimated by quantification of nucleic acids, was reduced by nearly 3.11 logaritms.
Conclusions:
These findings confirm that ERDRP is highly effective against a CoV. Experiments will be necessary to assess whether ERDRP is suitable for treatment of FIPV in vivo.
Insights
ERDRP-0519 effectively inhibits feline infectious peritonitis virus (FIPV) replication in cell cultures. This antiviral drug shows promise for treating FIPV, a fatal disease in cats, pending further in vivo studies.
Area of Science:
- Veterinary Virology
- Antiviral Drug Discovery
Background:
- Coronaviruses (CoVs) pose significant threats to human and animal health.
- Feline infectious peritonitis (FIP) is a fatal disease caused by Feline enteric coronavirus (FeCoV).
- Existing FIPV treatments are limited, necessitating novel antiviral strategies.
Purpose of the Study:
- To evaluate the in vitro antiviral efficacy of ERDRP-0519 (ERDRP) against Feline infectious peritonitis virus (FIPV).
Main Methods:
- In vitro antiviral assay using Crandell Reese Feline Kidney (CRFK) cells.
- Assessment of ERDRP's dose-dependent inhibition of FIPV replication.
- Quantification of viral load and infectivity reduction.
Main Results:
- ERDRP significantly inhibited FIPV replication in a dose-dependent manner.
- Viral infectivity decreased by up to 3.00 logarithms.
- Viral load reduced by nearly 3.11 logarithms in cell cultures.
Conclusions:
- ERDRP demonstrates high efficacy against a type II FIPV in vitro.
- Further in vivo experiments are required to determine ERDRP's therapeutic potential for FIP treatment.
